373110
Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea.
373110 (373110) - Net Assets
Latest net assets as of September 2024: ₩11.32 Billion KRW
Based on the latest financial reports, 373110 (373110) has net assets worth ₩11.32 Billion KRW as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩19.25 Billion) and total liabilities (₩7.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩11.32 Billion |
| % of Total Assets | 58.81% |
| Annual Growth Rate | 3.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 177.29 |
373110 - Net Assets Trend (2022–2024)
This chart illustrates how 373110's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 373110 (2022–2024)
The table below shows the annual net assets of 373110 from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩9.12 Billion | +282.67% |
| 2023-12-31 | ₩2.38 Billion | -71.90% |
| 2022-12-31 | ₩8.48 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to 373110's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1894873301000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩5.46 Billion | 59.85% |
| Other Components | ₩59.40 Billion | 651.25% |
| Total Equity | ₩9.12 Billion | 100.00% |
373110 Competitors by Market Cap
The table below lists competitors of 373110 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Noram Lithium Corp
OTCQB:NRVTF
|
$7.28 Million |
|
Danel (Adir Yeoshua) Ltd
TA:DANE
|
$7.28 Million |
|
Mangalam Global Enterprise Limited
NSE:MGEL
|
$7.28 Million |
|
RLF Agtech Ltd
AU:RLF
|
$7.28 Million |
|
Mudajaya Group Bhd
KLSE:5085
|
$7.27 Million |
|
Leishen Energy Holding Co., Ltd. Ordinary Shares
NASDAQ:LSE
|
$7.27 Million |
|
Biofrontera Inc
NASDAQ:BFRI
|
$7.27 Million |
|
The Good Flour Corp
PINK:GFCOF
|
$7.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 373110's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,383,503,590 to 9,121,059,290, a change of 6,737,555,700 (282.7%).
- Net loss of 9,543,173,500 reduced equity.
- Share repurchases of 15,875,138,820 reduced equity.
- Other factors increased equity by 32,155,868,020.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-9.54 Billion | -104.63% |
| Share Repurchases | ₩15.88 Billion | -174.05% |
| Other Changes | ₩32.16 Billion | +352.55% |
| Total Change | ₩- | 282.67% |
Book Value vs Market Value Analysis
This analysis compares 373110's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.80x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.92x to 1.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩783.32 | ₩1502.00 | x |
| 2023-12-31 | ₩220.08 | ₩1502.00 | x |
| 2024-12-31 | ₩835.38 | ₩1502.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 373110 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -104.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -493.35%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.85x
- Recent ROE (-104.63%) is above the historical average (-197.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -98.34% | -817.85% | 0.07x | 1.83x | ₩-9.19 Billion |
| 2023 | -389.36% | -825.74% | 0.11x | 4.39x | ₩-9.52 Billion |
| 2024 | -104.63% | -493.35% | 0.11x | 1.85x | ₩-10.46 Billion |
Industry Comparison
This section compares 373110's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 373110 (373110) | ₩11.32 Billion | -98.34% | 0.70x | $7.27 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |